A senior scientific researcher for one of the world’s most dynamic biotechnology companies, Genentech, has joined the Axenfeld-Rieger Foundation’s Scientific Advisory Board.
Dr Bailey Hannon is a member of the Translational Immunology Department where her work focuses on preclinical research and development of small and large molecular therapies for glaucoma.
As a biotechnology company, Genentech is a world leader in the development of groundbreaking scientific research to discover and develop medicines for people with serious diseases.
“I joined the Scientific Advisory Board after hearing about the severe lack of effective therapies for this rare, genetic form of glaucoma caused by Axenfeld-Rieger Syndrome” said Dr Hannon. “I hope to help the team by combining my PhD training and industry knowledge to help develop a treatment for this disease. I am thrilled to have the opportunity to be a part of and learn from such a fantastic Scientific Advisory Board.”
Rebecca Sloan, founder of the Axenfeld-Rieger Foundation, said: “Dr Hannon brings an industry perspective which will be invaluable to our efforts to identify and develop effective treatments for the glaucoma caused by Axenfeld-Rieger Syndrome. I’m excited to welcome her to the team”.
The Axenfeld-Rieger Foundation is on a mission to identify effective treatments for the difficult to manage form of glaucoma caused by Axenfeld-Rieger Syndrome.
Dr Alex Levin joins the Axenfeld-Rieger Foundation’s Scientific Advisory Board